BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17350323)

  • 1. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
    Milano A; Longo F; Basile M; Iaffaioli RV; Caponigro F
    Oral Oncol; 2007 Sep; 43(8):729-34. PubMed ID: 17350323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.
    Surakanti SG; Agulnik M
    Semin Oncol; 2008 Jun; 35(3):309-19. PubMed ID: 18544445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
    Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
    Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
    Erman M
    J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
    Dodd RL; Slevin NJ
    Oral Oncol; 2006 Sep; 42(8):759-69. PubMed ID: 16757203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update and perspectives on non-surgical treatment of salivary gland malignancies.
    Airoldi M; Cortesina G; Giordano C; Pedani F; Cavalot A; Marcato P; Beatrice F; Bumma C
    Acta Otorhinolaryngol Ital; 2003 Oct; 23(5):368-76. PubMed ID: 15108487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
    Prenen H; Kimpe M; Nuyts S
    Curr Opin Oncol; 2008 May; 20(3):270-4. PubMed ID: 18391625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cancer therapies.
    Blay JY; Le Cesne A; Alberti L; Ray-Coquart I
    Bull Cancer; 2005 Feb; 92(2):E13-8. PubMed ID: 15749638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
    Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
    Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly targeted therapies in advanced gastric cancer.
    Janjigian YY; Shah MA
    Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB-directed immunotherapy: antibodies in current practice and promising new agents.
    Friedländer E; Barok M; Szöllosi J; Vereb G
    Immunol Lett; 2008 Mar; 116(2):126-40. PubMed ID: 18201769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
    Agulnik M; Siu LL
    Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):543-51. PubMed ID: 15579019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
    Falchook GS; Lippman SM; Bastida CC; Kurzrock R
    Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
    Vattemi E; Graiff C; Sava T; Pedersini R; Caldara A; Mandarà M
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD; Moehler M
    Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.